The P53 gene acts to prevent cancer formation, thus acting as a tumor suppressor. P53 has been described as "the guardian of the genome" due to its role in maintaining stability by preventing genome mutation. In this experiment the Nrf protein was being tested to see if mutant P53 could control Nrf2 expression. Nrf is a key transcription factor that is used for the genes coding for antioxidants, detoxification enzymes, and multiple drug resistance to anti-cancer drugs. The hypothesis was that mutant P53 could in fact control Nrf2 expression at the transcriptional level, thereby presenting cisplatin resistance in non-small cell lung cancer also known as (NSCLC). A western blot analysis was done and in that analysis, Beta actin was used as the
